EBMT 2021 | VJHemOnc

Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Latest Videos

View all

Looking forward to the EBMT 2021 Annual Meeting

Nicolaus Kröger • 27 Jan 2021

Prednisone with or without ECP for GvHD

Daniel Couriel • 9 Mar 2021

REACT: ELISPOT assay predicts CMV reactivation in allo-HSCT patients

Roy Chemaly • 8 Mar 2021

HORIZON: melflufen plus dexamethasone shows efficacy in R/R myeloma

Maria Victoria-Mateos • 10 Mar 2021

Multiple Myeloma

View all

Cellular therapy: changing clinical practice for treatment of myeloma

Maria Victoria-Mateos • 10 Mar 2021

CAR-T for myeloma: ide-cel pending FDA approval

Nikhil Munshi • 22 Mar 2021

AML

View all

allo-SCT in refractory AML: FLAMSA approaches

Mohamad Mohty • 24 Feb 2021

FLT3 inhibitor maintenance after allo-SCT for AML

Nicolaus Kröger • 4 Mar 2021

ALL

View all

Omidubicel versus standard UCB transplantation

Guillermo Sanz • 8 Mar 2021

Haploidentical versus unrelated transplant in ALL

Arnon Nagler • 4 Mar 2021

Lymphoma

View all

CAR-T moving forwards for r/r DLBCL

Anna Sureda • 19 Mar 2021

MABs for Hodgkin lymphoma

Ali Bazarbachi • 12 Mar 2021

MRD

View all

Value of MRD in patients with NPM1-mutated AML

Farhad Ravandi • 11 Mar 2021

Latest developments in transplant for AML

Arnon Nagler • 4 Mar 2021

Response monitoring in multiple myeloma

Meral Beksac • 18 Mar 2021

Novel agents for consolidation after auto-SCT in myeloma

Nico Gagelmann • 16 Mar 2021

Immuno-Oncology

View all

Impact of novel therapies on post-transplant infection risk

Livio Pagano • 8 Mar 2021

Real-world data on CAR-T therapy for B-ALL

Stephan Grupp • 18 Mar 2021

The future of CAR-T and cellular therapy

Christian Chabannon • 12 Mar 2021

TGFb-resistant NK cells for hematological malignancies

Catherine Bollard • 23 Mar 2021